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Abstract
Considerable effort has been expended in attempting to distinguish genes that contribute to
initiating the onset of term and preterm labour (PTL) from those that change in expression as a
consequence of the progression of labour. The ability to define more clearly the genes involved in
triggering labour contractions should lead to the development of new effective and safer strategies
to prevent preterm birth. There is ample evidence to suggest that specific genes are co-ordinately
regulated within the upper and lower regions of the myometrium prior to and during parturition
and many of these genes are regulated by alternative pre-mRNA splicing. This mini-review
highlights that expression of a range of different splicing factors, with defined roles in pre-mRNA
splicing, is both temporally and spatially regulated within the uterine smooth muscle during
pregnancy and labour. Moreover, several of these splicing factors play key roles in controlling the
differential expression of specific regulatory proteins involved in uterine signalling and uterine
quiescence. In addition, antisense morpholino oligonucleotide manipulation of pre-mRNA splicing
may have potential in defining and targeting uterine pro-labour genes and thus contribute to the
development of new therapeutic approaches to prevent PTL.
Background
Splicing factors and myometrial genes
Alternative pre-mRNA splicing plays a major role in regu-
lating gene expression and generating protein diversity
and this mode of regulation appears to be particularly
prevalent in smooth muscle myogenesis and contractility
[1]. Myometrium is a unique smooth muscle organ that
differentiates during pregnancy into functionally distinct
upper and lower uterine regions. The myometrial proc-
esses regulating the activity of the uterus during gestation
and parturition are associated, in part, to the differential
expression and function of specific genes including:
cyclooxygenase ll (COX-2), oxytocin receptors, progester-
one receptors, specific prostaglandin receptors, cortico-
trophin-releasing hormone receptors (type 1), GTP-
binding proteins (Gαs) [2-5]. Most of these latter exam-
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ples exist as distinct protein isoforms generated from
alternate pre-mRNA splicing. Alternative splicing is a fun-
damental and tightly regulated RNA processing event that
involves a complex interplay of many different trans-act-
ing splicing factors and numerous cis-acting regulatory
elements present within the precursor mRNA sequences
of eukaryotic genes (Figure 1) [6]. Some of these splicing
regulatory proteins including SF2/ASF, hnRNPA1, SRp40,
SC35, PSF and U1-A snRNP are spatio-temporally regu-
lated within the upper and lower regions of the myo-
metrium during pregnancy (Figure 2) [7]. SF2/ASF and
hnRNPA1 have been studied extensively and have an
antagonistic relationship in which changes in the nuclear
concentration, ratio or activities of either protein can
switch the expression of specific isoforms [8] as illustrated
in Figure 3. In light of this it is not surprising that the
polarisation of SF2/ASF and hnRNPA1 proteins that exists
within the myometrium during pregnancy modulates the
expression of alternate spliced myometrial proteins. Evi-
dence indicates that both SF2/ASF and hnRNPA1 contrib-
ute to the up-regulation of the myometrial Gαs spliced
variants that occurs during pregnancy [9]. Up-regulation
of Gαs isoforms together with Gαs coupled adenylyl
cyclase activity results in elevated cAMP levels [10], which
has been proposed to be important for the maintenance
of myometrial quiescence during gestation [11]. Interest-
ingly, other components of the cAMP signalling pathway
also undergo distinct patterns of alternate splicing within
the myometrium during pregnancy; examples include
adenylyl cyclase isoforms [12], the cAMP-dependent tran-
scription factors, cAMP-response element modulator pro-
teins, CREM (CREMτ2α and CREMα) and the activating
transcription factor 2 (ATF-2) [13]. Alternative splicing of
CREM promotes a 'switch' within the myometrium during
pregnancy and labour from production of CREMτ2α, a
potent transcriptional activator to the synthesis of
CREMα, a transcriptional repressor. These changes in
splicing patterns are primarily controlled by the differen-
Factors involved in alternative pre-mRNA splicing Figure 1
Factors involved in alternative pre-mRNA splicing. (A) Co-localisation of the antagonistic splicing factors SF2/ASF and 
hnRNPA1 within the nuclei of human myometrial cells by fluorescence confocal microscopy; Nuclei (blue) were defined by 
staining with 4',6-diamidino-2-phenylindole (DAPI) which binds to double stranded DNA; Co-localisation of SF2/ASF (green flu-
orescence) and hnRNPA1 (red fluorescence) was observed using monoclonal antibodies specific to each protein. (B) Regula-
tion of alternative pre-mRNA splicing involves many different nuclear trans-acting splicing factors (SF), such as SR protein 
members, e.g SF2/ASF and hnRNPs, e.g hnRNPA1 and snRNPs that recognise and interact with numerous cis-acting RNA 
motifs present within the pre-mRNA sequence of genes; these include 5'donor and 3'acceptor sites at exon: intron boundaries, 
exon and intron enhancer elements (ESE, ISE) which can promote the use of specific splice sites; exon and intron silencer ele-
ments (ESS, ISS) which can when bound by hnRNPs repress the use of specific splice sites. Coloured boxes represent alterna-
tively spliced exons.
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Spatial and temporal expression of splicing factors in the myometrium during pregnancy Figure 2
Spatial and temporal expression of splicing factors in the myometrium during pregnancy. (A) SF2/ASF, 
hnRNPA1, SRp40, SC35, PSF and UI-A snRNP protein expression within the upper and lower uterine regions of the human 
myometrium. Data are shown as the mean (n = 10) for non-pregnant (NP), term not in labour; upper (PU) and lower uterine 
regions and labouring upper (LU) and lower uterine regions (LL). (B) The switch in the expression of SF2/ASF, hnRNPA1, 
SRp40, SC35, PSF and UI-A snRNP within the upper and lower uterine regions from the non-pregnant to the term pregnant is 
indicated (red). Differential expression profiles for spliced variants of the transcriptional factors CREMτ2α, CREMα and ATF-2 
are also shown (black).
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Cartoon indicating the effect that changes in expression of splicing factors can have on the expression myometrial genes Figure 3
Cartoon indicating the effect that changes in expression of splicing factors can have on the expression myome-
trial genes. Fluctuations in the levels, ratios and activity of myometrial nuclear splicing factors in pregnancy may influence the 
expression of substrate-specific pre-mRNAs and in turn influence and switch the expression and ratios of the specific protein 
isoforms that are generated. In theory, changes in the levels of splicing factors could generate a) proteins with enhanced activ-
ity; b) proteins with different functions; c) proteins with abolished functions and d) provide a means to regulate gene expres-
sion by increasing the rate of nonsense-mediated decay of affected mRNAs.
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tial expression and activity of the splicing factor, SRp40
(Figure 2) and multiple SRp40 binding RNA motifs that
are present within the alternatively spliced exons of CREM
[14]. Since there is ample evidence for the physiological
relevance of CREM mediated gene regulation, these
changes in the expression of functionally distinct CREM
spliced variants are likely to have biological consequences
on the expression of down-stream target genes involve in
uterine activity during gestation and parturition.
Targeting pro-labour genes with antisense morpholino oligonucleotides Figure 4
Targeting pro-labour genes with antisense morpholino oligonucleotides. (A) Diagram to show mechanism of action 
of morpholino oligonucleotides (MOs) in targeting nuclear pre-mRNA. Binding of (MOs) to the 5' and 3' splice site boundaries 
blocks access by splicing factors (SF) to the splice sites and redirects the splicing machinery to skip out the exon. This results in 
a shortened mRNA transcript and a truncated protein or no protein. (B) Effect of MOs targeted to the pre-mRNA of exon 4 
of the COX-2 gene. Substantial inhibition by MOs of COX-2 protein expression, induced by LPS, was observed at the protein 
level, means ± S.E.M. (n = 6). (C) Loss of enzyme activity due to MOs inhibition was also determined; this assay measures 
COX-2 activity by calculating the rate of conversion of arachidonic acid to PGH2 [18]. Data shown as % inhibition. Data are 
mean ± S.E.M. (n = 6).
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Antisense oligonucleotides as modulators of myometrial 
alternative splicing
The use of antisense oligonucleotides to manipulate the
expression of genes in vitro is well established [15,16]. Var-
ious chemically modified antisense systems have been
used against several 'disease-causing genes', such as the
dystrophin gene and the survival of motor neuron gene
(SMN2), to manipulate the consequences of mutations
present at splice sites that would normally generate an
aberrant or truncated protein [16]. The ability to modify
the alternative splicing pattern(s) of genes by targeting
pre-mRNA with antisense oligonucleotides has also pro-
vided a useful experimental strategy to elucidate the func-
tion of different ratios of spliced variants and a potential
therapeutic strategy to increase/decrease the ratio of spe-
cific spliced variants known to be associated with certain
cancers and other diseases [16,17]. A similar approach has
been adopted to use antisense oligonucleotides to switch
splice site selection and redirect the splicing machinery to
skip out exons that encode for either a functional domain
or induces a premature stop codon. In principal this gen-
erates a protein devoid of functional domains or no pro-
tein at all (Figure 4A). A similar strategy could therefore be
utilised to define and suppress the activation of specific
genes that may trigger the onset of term and preterm
labour. COX-2 is one such gene that has been implicated
in contributing to the onset of both term and preterm
labour. It has recently been shown that morpholino oligo-
nucleotides targeted to both the 5' donor and 3'acceptor
splice site boundaries of the exon 4 of COX-2 pre-mRNA
significantly inhibited the expression and activity of this
enzyme (induced by lipopolysaccharide) in both myome-
trial and amnion-derived cultured cell monolayers [18].
Morpholino antisense oligonucleotides have a number of
advantages over other gene silencing systems; they are
DNA analogues so are resistant to enzymatic degradation;
they have very low toxicity; long term activity; excellent
target specificity compared to alternative gene-silencing
systems; consequently they represent a highly specific and
non-toxic technique to define the function and silence
specific genes.
Conclusion
To summarise, alternative splicing plays an important role
in modulating myometrial gene regulation during preg-
nancy and labour by naturally increasing the coding
capacity of myometrial mRNA transcripts to generate dif-
ferent protein isoforms with enhanced activity and also
isoforms with markedly different activities. This mini-
review proposes that alternative splicing within the myo-
metrium during pregnancy, term and preterm labour is
not likely to be a static process but subject to change. The
expression profiles for splicing factors change dramati-
cally within the myometrium in pregnancy; these factors
have been shown to have substrate-specific roles in alter-
native splicing and it is possible that they may modulate
the expression of many more alternately spliced myome-
trial proteins involved in myometrial quiescence and con-
tractility. Therefore, a more complete analysis of
alternative splicing events coupled with transcriptional
control of myometrial genes would be advantageous to
increase our understanding of the complex co-ordinated
molecular processes that regulate myometrial genes in
pregnancy and labour. Finally, the use of highly specific
antisense morpholino oligonucleotides may prove to be a
valuable technique to identify and 'switch off' specific
genes the activation of which is linked with the initiation
of term and preterm labour.
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